Predicting Ipsilesional Motor Deficits in Stroke with Dynamic Dominance Model
Some stroke patients have severe weakness in one arm and must rely on their less-affected arm for daily activities. Previous research has shown that in some patients, the less-affected arm also experiences weakness due to the stroke. This research is being done to find out if the less-affected arm can be trained to perform faster and better during daily activities. Approximately 180 people will take part in this research study at Hershey Medical Center and University of Southern California.
A Clinical Research Study for Adults Living with Stable Vitiligo
<p>The purpose of this study is to evaluate the safety and effectiveness of a procedure using the RECELL® System for repigmentation of stable vitiligo. Stable vitiligo means that for at least 12 months: </p><p>• Areas affected by loss of pigment have not increased in size. </p><p>• No new areas with pigment loss have developed. </p><p>The RECELL System is used to prepare a suspension (a liquid solution) of skin cells using a small sample of your own pigmented skin. The suspension made using your own skin includes cells responsible for pigmentation and will be applied on a depigmented area of your skin.</p>
Testing a new drug to prevent Alzheimer's disease and dementia
<p>Do any of your friends, family, or loved ones have problems remembering or have developed Alzheimer’s disease? The USC Alzheimer Disease Research Center is testing how well a drug may help to prevent the loss of memory. The research team is looking for volunteers (ages 60 to 75) who do not have signs of cognitive problems (meaning that their speech, thinking, and memory are fine compared to other people of the same age). </p><p>If you're eligible and choose to take part, you'll be one of the few people that can join the fight against Alzheimer's disease. But preventing such a disease won't happen overnight. The trial will run for between 5 and 8 years.</p>
Not yet recruiting | Alzheimer's Disease | Not Multisite
Need Help Quitting Cigarettes?
<p>Do you want to quit smoking, but not sure how? Are you having a hard time finding resources to help you take the first step towards quitting?</p><p>The researchers at the USC Health, Emotion, and Addiction Laboratory are looking for cigarette smokers between the ages of 21 and 65 years old who want to kick the habit.</p><p><br></p><p><br></p>
USC study investigates the benefits or health risks of vaping and smoking
Researchers at USC are seeking study participants who vape or smoke as well as non-smokers in the Los Angeles area. The purpose of the research is to study the health benefits and risks of electronic cigarettes (e-cigs). Your participation will help to better understand the potential effects of e-cigs on the human body.
A Multicenter, Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment with Cimzia
This is a multicenter prospective study evaluating the placental transfer of certolizumab pegol (CZP) by measuring concentration of CZP in infants born to mothers who are on this drug during pregnancy. Certolizumab is a drug that is approved for use in Crohn's disease, rheumatoid arthritis and ankylosing spondylitis. Recent evidence suggests that certolizumab pegol does not cross the placenta, unlike other anti-tumor necrosis factor drugs. The primary objective of this study is to assess whether there is transfer of CZP across theplacenta to infants from mothers by evaluating the concentration of CZP in the plasma of infants. Blood samples will be measured in the infant, mother, and umbilical cord at birth. Additionally, blood samples will be collected from the infant at Week 4 and Week 8 after birth in order to assess the pharmacokinetics (PK) of CZP in infants after birth. The secondary and exploratory objectives are to assess the concentrations of CZP, anti-CZPantibodies, and polyethylene glycol (PEG) in the 3 sources of blood samples at the time of birth(infant, mother, and umbilical cord) and in the infants at 4 weeks and 8 weeks after birth. Although this study is noninterventional regarding treatment with CZP, it is consideredinterventional due to the collection of blood samples that are not part of routine clinical practice.The study will only include pregnant women who have decided to continue or start treatment withCZP for an approved indication in accordance with their treating physician prior to beingrecruited into the study. Approximately 30 pregnant subjects are planned to be screened in order to enroll 20 subjects (blood samples provided by the mother and infant at delivery/birth). To beeligible to participate in the study, subjects must be 30 weeks pregnant at the start of screening,and expecting to use CZP within 35 days prior to expected delivery date. The primary PK variable is plasma concentration of CZP in the infant at birth. Secondary andexploratory variables include plasma concentrations of CZP, anti-CZP antibodies, and PEG. In addition, safety variables are adverse events (AEs) which will be assessed by a Safety Follow-up phone assessment for mother and infant performed 5 weeks (5 days) after the final sample is obtained. Subjects who withdraw prematurely will have a Safety Follow-Up telephone contact (for mother and infant) 5 weeks (5 days) after withdrawing from the study.
A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
This is an open label, multi-center, single arm phase II study. The study will investigate
the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of
patients with recurrent or persistent PrR-negative endometrial cancer.
Eligible patients will be enrolled into the study and administered sodium cridanimod in
combination progestin therapy. Objective responses will be assessed at 12 week intervals.
Patients will be treated for a 12 month period, followed by an additional 12 month follow up
period or to disease progression whichever occurs first.
Important objectives of the study are to investigate the effect of sodium cridanimod in
conjunction with progestin therapy on the level of PrR in tumor tissue and how this
correlates to efficacy. To accomplish this objective, some of the patients enrolled in the
study will undergo two tumor biopsies that will allow measurement of PrR levels in the tumor
tissue before the treatment and after 4 weeks of therapy.
Powered by
SC CTSI